Tumor News and Research RSS Feed - Tumor News and Research

Aeterna Zentaris selects optimized Erk inhibitor molecule for further development

Aeterna Zentaris selects optimized Erk inhibitor molecule for further development

Aeterna Zentaris Inc. today announced it has selected an optimized Erk inhibitor molecule for development, thus achieving another important milestone in the development of a new class of potential cancer therapies. [More]
Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. [More]
German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. [More]
Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2015. [More]
LMU researchers reveal role of mutations in development of Ewing's sarcoma

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Researchers from Ludwig-Maximilians-Universitaet in Munich have elucidated at the molecular level how an otherwise innocuous inherited mutation that is quite common in European populations interacts with a spontaneous somatic mutation to promote the development of Ewing's sarcoma. [More]
Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. [More]
New technique improves survival time for glioblastoma patients by 50%

New technique improves survival time for glioblastoma patients by 50%

The rapid spread of a common and deadly brain tumor has been slowed down significantly in a mouse model by cutting off the way some cancer cells communicate, according to a team of researchers that includes UF Health faculty. [More]
Yale researchers confirm NF1 gene as major player in development of skin cancer

Yale researchers confirm NF1 gene as major player in development of skin cancer

A multidisciplinary team at Yale, led by Yale Cancer Center members, has defined a subgroup of genetic mutations that are present in a significant number of melanoma skin cancer cases. Their findings shed light on an important mutation in this deadly disease, and may lead to more targeted anti-cancer therapies. [More]
Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Scientists reveal potential therapeutic approach to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a very aggressive form of pulmonary fibrosis and has a particularly poor prognosis. This fatal disease, for which so far no causal therapies exist, is characterized by a massive deposition of connective and scar tissue in the lung, which leads to a progressive loss of lung function and ultimately death. [More]
Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. [More]
Protein imbalances within cells can cause ovarian cancer

Protein imbalances within cells can cause ovarian cancer

Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found. The discovery is a major breakthrough because, until now, genetic aberrations have been seen as the main cause of almost all cancer. [More]
Study: Omega-3 fatty acids may help improve treatment response, quality of life for patients with cancer

Study: Omega-3 fatty acids may help improve treatment response, quality of life for patients with cancer

Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom. [More]
Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and Hannover has now succeeded in decoding a specific form of this leukemia, which is regarded as incurable, and in obtaining insights for new therapeutic possibilities. [More]
Simple and accurate detection system can redefine medical diagnostics field

Simple and accurate detection system can redefine medical diagnostics field

In biology and medicine, we often need to detect biological molecules. For example, in cancer diagnostics, doctors need quick and reliable ways of knowing if tumor cells are present in the patient's body. [More]
Study points to new treatment strategies for liver cancer

Study points to new treatment strategies for liver cancer

A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

An algorithm dubbed ENVE could be the Google for genetic aberrations — and it comes from Case Western Reserve. [More]
3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million. [More]
Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy. [More]
Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards. [More]
Advertisement
Advertisement